Climb Bio, Inc. (CLYM)
9.25
-0.03
(-0.32%)
USD |
NASDAQ |
Nov 20, 10:47
Climb Bio Cash from Investing (Quarterly) : 6.40M for Sept. 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 6.40M |
| June 30, 2026 | -57.26M |
| March 31, 2026 | -12.96M |
| December 31, 2025 | 25.54M |
| September 30, 2025 | 15.26M |
| June 30, 2025 | 4.786M |
| March 31, 2025 | -42.75M |
| December 31, 2024 | -53.41M |
| September 30, 2024 | -71.79M |
| June 30, 2024 | -9.645M |
| March 31, 2024 | 13.75M |
| December 31, 2023 | 36.75M |
| September 30, 2023 | 28.04M |
| June 30, 2023 | -1.601M |
| Date | Value |
|---|---|
| March 31, 2023 | 5.797M |
| December 31, 2022 | 14.28M |
| September 30, 2022 | 8.509M |
| June 30, 2022 | 15.69M |
| March 31, 2022 | -4.035M |
| December 31, 2021 | -8.051M |
| September 30, 2021 | -106.92M |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Korsana Biosciences, Inc. | -0.231M |
| Cullinan Therapeutics, Inc. | 51.64M |
| Q32 Bio, Inc. | -0.052M |
| Oncolytics Biotech, Inc. | -0.0069M |
| Sangamo Therapeutics, Inc. | -0.013M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -12.00M |
| Cash from Financing (Quarterly) | 1.224M |
| Free Cash Flow | -53.64M |
| Free Cash Flow Per Share (Quarterly) | -0.1602 |
| Free Cash Flow to Equity (Quarterly) | -12.57M |
| Free Cash Flow to Firm (Quarterly) | -12.82M |
| Free Cash Flow Yield | -10.05% |